Business
VAXXA: Q3 2024 net sales more than doubled year-over-year, with EBITDA turning positive
VAXXA: Q3 2024 net sales more than doubled year-over-year, with EBITDA turning positive
About this update from Vaxxa Ab
Net sales more than doubled year-over-year in Q3 2024, with improved EBITDA and a strong cash position. A new platform launch and strategic hiring are set to drive further growth. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.